➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Merck
Medtronic
Johnson and Johnson
McKesson

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Claims for Patent: 5,698,421

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 5,698,421
Title: Ribonucleoprotein particles for cleaving double-stranded DNA and inserting an RNA/DNA molecule into the cleavage site
Abstract:The present invention provides new methods, employing a nucleotide integrase, for cleaving double-stranded and single stranded DNA substrates at specific sites and for attaching nucleic acid molecules to the cleaved DNA substrates. One method uses a nucleotide integrase to cleave one strand of a double-stranded DNA and to concomitantly attach a nucleic acid molecule to the cleaved strand. Another method uses a nucleotide integrase to cleave both strands of a double-stranded DNA substrate and to attach a nucleic acid molecule to one strand of the DNA substrate. Another method uses a nucleotide integrase to cleave both strands of a double-stranded DNA substrate and to attach an RNA molecule to one strand of the substrate and for attaching a cDNA to the other strand of the substrate. Another method cleaves single stranded DNA with the concomitant insertion of a nucleic acid molecule at the cleavage point. The nucleotide integrase comprises an RNP particle which comprises a group II intron RNA bound to a group II intron encoded protein. The present invention also relates to purified and reconstituted RNP particles and reconstituted RNP that cleave DNA substrates.
Inventor(s): Lambowitz; Alan M. (Columbus, OH), Zimmerly; Steven (Columbus, OH), Yang; Jian (Columbus, OH), Guo; Huatao (Columbus, OH)
Assignee: The Ohio State Research Foundation (Columbus, OH)
Application Number:08/526,964
Patent Claims:1. A reconstituted RNP particle preparation comprising:

(a) an RNA-protein complex comprising:

(i) a protein having an amino acid sequence encoded by a group II intron, an X domain and a Zn domain; and

(ii) an RNA molecule that is selected from the group consisting of an rRNA, an mRNA of a splicing defective group II intron RNA which encodes said protein and which comprises flanking exons, an mRNA which does not encode said protein, and an excised group II intron RNA which does not encode said protein; wherein said RNA molecule is not an excised group II intron RNA molecule which encodes said protein; and wherein said RNA molecule is bound to said protein to form said RNA-protein complex;

(b) a reconstituted RNP particle that cleaves a DNA substrate at a specific site, said reconstituted RNP particle comprising:

(i) a protein having an amino acid sequence encoded by a group II intron, an X domain and a Zn domain; and

(ii) an exogenous RNA which is a synthetic transcript of a group II intron bound to said protein to form said reconstituted RNP particle, wherein said exogenous RNA lacks flanking exons and comprises a sequence which encodes said protein and a hybridizing sequence which is complementary to a recognition site on one strand of the DNA substrate.

2. The reconstituted RNP particle preparation of claim 1 wherein:

the exogenous RNA comprises a synthetic transcript of a yeast mitochondrial group II intron and the protein comprises an amino acid sequence encoded by a yeast mitochondrial group II intron.

3. The reconstituted RNP particle preparation of claim 1 wherein:

the exogenous RNA comprises a synthetic transcript of the group II intron aI2 of the yeast mitochondrial COX1 gene and said protein comprises an amino acid sequence encoded by the group II intron AI2 of the yeast mitochondrial COX1 gene.

4. The reconstituted RNP particle preparation of claim 1 further comprising an exogenous RNA which is a synthetic transcript of a group II intron, wherein said exogenous RNA lacks flanking exons and comprises a sequence which encodes said protein and a hybridizing sequence which is complementary to a recognition site on one strand of the DNA substrate.

5. A purified reconstituted RNP particle comprising:

(a) a protein having an amino acid sequence encoded by a group II intron; and

(b) an exogenous RNA which is a synthetic transcript of the group II intron which encodes said protein, wherein said exogenous RNA lacks flanking exons and comprises a hybridizing sequence which is complementary to a recognition site on a DNA substrate; and

wherein said protein is bound to said RNA to form a reconstituted RNP particle that is capable of cleaving the DNA substrate.

6. A purified RNP particle consisting essentially of:

(i) an excised group II intron RNA having a hybridizing region having a sequence which is complementary to a recognition site on one strand of a DNA substrate;

(ii) a protein bound to said group II intron RNA, said protein comprising an amino acid sequence which is encoded by a group II intron, an X domain and a Zn domain;

wherein said RNP particle is capable of cleaving the DNA substrate.

7. The purified RNP particle of claim 6 wherein said group II intron RNA has six domains and said protein further comprises a reverse transcriptase domain.

8. The purified RNP particle of claim 7 wherein said RNA comprises a yeast mitochondrial group II intron RNA and said protein comprises an amino acid sequence encoded by a yeast mitochondrial group II intron.

Details for Patent 5,698,421

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04 ⤷  Free Forever Trial The Ohio State Research Foundation (Columbus, OH) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04 ⤷  Free Forever Trial The Ohio State Research Foundation (Columbus, OH) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04 ⤷  Free Forever Trial The Ohio State Research Foundation (Columbus, OH) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Harvard Business School
Dow
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.